

05 May 2026

New US patent filed to advance TRP-8803 IBS program

- **US Provisional Patent Application (No. 64/055,765) filed**
- **Filing underpinned by new Phase 2a clinical data in treatment-resistant IBS patients, presented at DDW 2026 by researchers from Massachusetts General Hospital and Columbia University**
- **Phase 2a study delivered 75% response rate in treatment-resistant IBS patients, significantly exceeding existing IBS therapies, which typically demonstrate 17–44% response rates**
- **Complements existing Australian patent covering precision-controlled psilocybin/psilocin delivery, with protection through to 2042**
- **Supports Entropy's US-focused development and partnering strategy for TRP-8803**
- **Enhances long-term exclusivity and strategic positioning in a large, underserved gut-brain disorder market**

Melbourne, Australia – Entropy Neurodynamics Limited ('Entropy Neurodynamics', 'ENP' or the 'Company') (ASX: ENP), a clinical-stage biotechnology company, is pleased to advise it has filed US Provisional Patent Application No. 64/055,765.

The new filing is in addition to Entropy's existing international patent application related to psychedelic-assisted therapy for disorders of gut-brain interaction, which was filed under the Patent Cooperation Treaty (PCT) on 3 January 2024.

Together, these filings expand and strengthen the Company's intellectual property position by establishing multiple patent families covering both foundational concepts and new clinical-data-driven therapeutic insights.

The most recent filing is based on new clinical insights from the results of the Company's Phase 2a Clinical Study of TRP-8802 (oral psilocybin) in patients with treatment-resistant, irritable bowel syndrome (IBS). These results were presented at Digestive Disease Week (DDW) 2026, the world's leading gastroenterology congress, by researchers from the original and largest teaching hospital of Harvard Medical School, Massachusetts General Hospital (MGH) and Columbia University (refer ASX announcement: 4 May 2026).

Results highlighted a 75% response rate in treatment-resistant IBS patients, which represents a distinct treatment breakthrough compared to existing therapies that deliver 17-44% response rates, making them the strongest clinical signal ever reported in IBS drug development.

If granted, this new patent family would complement Entropy's existing TRP-8803 portfolio and support the Company's ongoing US focused development and partnering strategy.

Potential new patents will also complement the Company's existing Australian patent covering the its novel, precision-controlled method of administering psilocybin, psilocin and related forms to treat a range of psychological and nociplastic pain disorders (refer ASX announcement: 12 February 2026). This Australian patent underpins the Company's lead asset TRP-8803 (IV-infused psilocin) and provides long-



dated IP protection through to 2042.

Management commentary:

CEO, Mr Jason Carroll said: *“Building on our existing PCT application and TRP-8803 patent portfolio, this filing materially strengthens Entropy’s IP position at a critical inflection point in clinical development. Importantly, the application is grounded in robust, human clinical data, reinforcing both the novelty and translational relevance of our approach in treatment-resistant IBS.*

We believe this expanded IP architecture establishes a defensible and scalable foundation across both oral and IV-delivered psychedelic therapies, supporting long-term exclusivity in a large, underserved market. It also enhances the strategic value of TRP-8803 as we advance our US-focused development and partnering initiatives, positioning Entropy as a leader in the emerging field of gut-brain targeted psychedelic therapies.”

Investor webinar

The Company advises a webinar will be held at 10:30am AEST (8:30am AWST) on Wednesday, 6 May 2026, hosted by CEO Mr Jason Carroll.

The webinar will be followed by a Q&A session. Questions can be submitted to henry.jordan@sdir.com.au prior to, or in written form, during the webinar. Anyone wishing to attend the webinar must register via the following:

- https://us02web.zoom.us/webinar/register/WN_i8Pyag-KRAWpiJkPOHmq9g

A recording of the presentation will be made available following the webinar

This announcement has been authorised by the Board of Entropy Neurodynamics

- ENDS -

INVESTOR & MEDIA CONTACT:

Jason Carroll
Chief Executive Officer
Entropy Neurodynamics Limited
jcarroll@entropyneurodynamics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Entropy Neurodynamics Limited

Entropy Neurodynamics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.

For personal use only



Development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. Results from each of these trials demonstrated the clinical benefits of psychedelic therapy and will be used to further enhance the development of TRP-8803.

Register for updates

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done by:

- Go to investor.automic.com.au
- If you're an existing user, log in with your username and password
- If you're a new user, click 'register', select 'Entropy Neurodynamics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.
- Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimen used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Entropy Neurodynamics as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Company's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Entropy Neurodynamics; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.